136 related articles for article (PubMed ID: 15541413)
1. In vivo distribution of a vaginal gel: MRI evaluation of the effects of gel volume, time and simulated intercourse.
Barnhart KT; Pretorius ES; Timbers K; Shera D; Shabbout M; Malamud D
Contraception; 2004 Dec; 70(6):498-505. PubMed ID: 15541413
[TBL] [Abstract][Full Text] [Related]
2. Distribution of a vaginal gel (Invisible Condom) before, during and after simulated sexual intercourse and its persistence when delivered by two different vaginal applicators: a magnetic resonance imaging study.
Omar RF; Trottier S; Brousseau G; Lamarre A; Alexandre Gagnon ; Bergeron MG
Contraception; 2008 Jun; 77(6):447-55. PubMed ID: 18477496
[TBL] [Abstract][Full Text] [Related]
3. Distribution of a 3.5-mL (1.0%) C31G vaginal gel using magnetic resonance imaging.
Barnhart KT; Pretorius ES; Timbers K; Shera D; Shabbout M; Malamud D
Contraception; 2005 May; 71(5):357-61. PubMed ID: 15854637
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial to determine the distribution of four topical gel formulations in the human vagina.
Barnhart K; Kulp JL; Rosen M; Shera DM
Contraception; 2009 Apr; 79(4):297-303. PubMed ID: 19272499
[TBL] [Abstract][Full Text] [Related]
5. Magnetic resonance imaging to determine the distribution of a vaginal gel: before, during, and after both simulated and real intercourse.
Pretorius ES; Timbers K; Malamud D; Barnhart K
Contraception; 2002 Dec; 66(6):443-51. PubMed ID: 12499038
[TBL] [Abstract][Full Text] [Related]
6. The optimal analysis of MRI data to quantify the distribution of a microbicide.
Barnhart KT; Pretorius ES; Shera DM; Shabbout M; Shaunik A
Contraception; 2006 Jan; 73(1):82-7. PubMed ID: 16371301
[TBL] [Abstract][Full Text] [Related]
7. A Phase I study of the functional performance, safety and acceptability of the BufferGel Duet.
Ballagh SA; Brache V; Mauck C; Callahan MM; Cochon L; Wheeless A; Moench TR
Contraception; 2008 Feb; 77(2):130-7. PubMed ID: 18226678
[TBL] [Abstract][Full Text] [Related]
8. Postcoital testing after the use of a bio-adhesive acid buffering gel (ACIDFORM) and a 2% nonoxynol-9 product.
Amaral E; Perdigão A; Souza MH; Mauck C; Waller D; Zaneveld L; Faúndes A
Contraception; 2004 Dec; 70(6):492-7. PubMed ID: 15541412
[TBL] [Abstract][Full Text] [Related]
9. Vaginal distribution of two volumes of the novel microbicide gel cellulose sulfate (2.5 and 3.5 mL).
Barnhart KT; Pretorius ES; Shaunik A; Timbers K; Nasution M; Mauck C
Contraception; 2005 Jul; 72(1):65-70. PubMed ID: 15964295
[TBL] [Abstract][Full Text] [Related]
10. Mucosal integrity and inflammatory markers in the female lower genital tract as potential screening tools for vaginal microbicides.
Su HI; Schreiber CA; Fay C; Parry S; Elovitz MA; Zhang J; Shaunik A; Barnhart K
Contraception; 2011 Nov; 84(5):525-32. PubMed ID: 22018129
[TBL] [Abstract][Full Text] [Related]
11. Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women.
Nel AM; Coplan P; van de Wijgert JH; Kapiga SH; von Mollendorf C; Geubbels E; Vyankandondera J; Rees HV; Masenga G; Kiwelu I; Moyes J; Smythe SC
AIDS; 2009 Jul; 23(12):1531-8. PubMed ID: 19550287
[TBL] [Abstract][Full Text] [Related]
12. A randomized Phase I vaginal safety study of three concentrations of C31G vs. Extra Strength Gynol II.
Mauck CK; Weiner DH; Creinin MD; Barnhart KT; Callahan MM; Bax R
Contraception; 2004 Sep; 70(3):233-40. PubMed ID: 15325893
[TBL] [Abstract][Full Text] [Related]
13. A randomized, placebo-controlled trial to assess the safety and acceptability of use of carraguard vaginal gel by heterosexual couples in Thailand.
Kilmarx PH; Blanchard K; Chaikummao S; Friedland BA; Srivirojana N; Connolly C; Witwatwongwana P; Supawitkul S; Mock PA; Chaowanachan T; Tappero J
Sex Transm Dis; 2008 Mar; 35(3):226-32. PubMed ID: 18490865
[TBL] [Abstract][Full Text] [Related]
14. Differentiating normal from abnormal rates of genital epithelial findings in vaginal microbicide trials.
van de Wijgert JH; Kilmarx PH; Jones HE; Karon JM; Chaikummao S
Contraception; 2008 Feb; 77(2):122-9. PubMed ID: 18226677
[TBL] [Abstract][Full Text] [Related]
15. Safety studies of a recently developed microbicidal contraceptive gel (UniPron) in female baboons (Papio anubis).
Mburu N; Obiero JA; Waititu K; Mwaura BN; Orawo JO; Farah IO; Mwethera PG
Afr J Reprod Health; 2009 Dec; 13(4):95-104. PubMed ID: 20690277
[TBL] [Abstract][Full Text] [Related]
16. A Pilot Study Measuring the Distribution and Permeability of a Vaginal HIV Microbicide Gel Vehicle Using Magnetic Resonance Imaging, Single Photon Emission Computed Tomography/Computed Tomography, and a Radiolabeled Small Molecule.
Fuchs EJ; Schwartz JL; Friend DR; Coleman JS; Hendrix CW
AIDS Res Hum Retroviruses; 2015 Nov; 31(11):1109-15. PubMed ID: 26077739
[TBL] [Abstract][Full Text] [Related]
17. Mucosal toxicity studies of a gel formulation of native pokeweed antiviral protein.
D'Cruz OJ; Waurzyniak B; Uckun FM
Toxicol Pathol; 2004; 32(2):212-21. PubMed ID: 15200159
[TBL] [Abstract][Full Text] [Related]
18. [Lubrication reduces difficulties during sexual intercourse after gynecological surgery].
Picha E
Akush Ginekol (Sofiia); 2002; 41 Suppl 1():33-5. PubMed ID: 12412353
[No Abstract] [Full Text] [Related]
19. Vaginal distribution of Replens and K-Y Jelly using three imaging techniques.
Mauck CK; Katz D; Sandefer EP; Nasution MD; Henderson M; Digenis GA; Su I; Page R; Barnhart K
Contraception; 2008 Mar; 77(3):195-204. PubMed ID: 18279691
[TBL] [Abstract][Full Text] [Related]
20. Universal vaginal applicator for the uniform distribution of vaginal gel and cream formulations: a magnetic resonance imaging study.
Omar RF; Trottier S; Brousseau G; Ouellet C; Danylo A; Ong T; Bergeron MG
J Obstet Gynaecol Can; 2014 Jan; 36(1):42-50. PubMed ID: 24444286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
